Skip to main content

Market Overview

D. Medical Announces Retention of Financial Advisor

Share:

TIRAT CARMEL, Israel, June 11, 2012 (GLOBE NEWSWIRE) -- D. Medical Industries Ltd. (Nasdaq: DMED) (TASE:DMED) ("D. Medical" or the "Company") announced today that it has retained Chicago-based Healthios Capital Markets, LLC, a leading advisory firm focused on the emerging growth healthcare community, as its financial advisor in connection with the Company's previously disclosed strategic reorganization and with the goal of supporting the Company in achieving a strategic partnership.

Interested parties are invited to contact the Company's financial advisor per the contact information listed below. The Company noted that there can be no assurance that the process will result in a transaction that the Company's Board determines is in the best interests of the Company or its shareholders. Further, there is no assurance concerning the type, form, structure, nature, results, timing or terms and conditions of any such transaction, even if a transaction does result from this process. The Company may not disclose developments with respect to this process unless and until its Board of Directors has approved a specific transaction.

Financial advisor contact information:

W. Gregory Shearer
Managing Director
Healthios Capital Markets, LLC
Tel: (847) 400-5000
Email: dloucks@healthios.com

About D. Medical

D. Medical is a medical device company that holds through its subsidiaries a portfolio of products and intellectual property in the area of insulin and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. For more information, please visit http://www.dmedicalindustries.com (corporate) and http://www.springnow.com (healthcare professionals, patients and care givers).

Forward-Looking Statements

This press release contains forward-looking statements (as defined by the Israeli Securities Law, 1968, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties. These statements include, forecasts, goals, uncertainties and assumptions and relate, inter alia, to D. Medical's business relationship with Healthios Capital Markets, LLC, and any potential transaction that may arise in connection with such business relationship. The forward-looking statements are based on D. Medical's current expectations and beliefs which are based on, among other things, its analysis of publicly available information and market research reports. All forward-looking statements are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or of any of them will transpire or occur, what impact it will have on D. Medical's results of operations or financial condition. D. Medicals does not undertake to update any forward-looking statements.

CONTACT: Company Contact: Amir Loberman Chief Financial Officer D. Medical Industries LTD T: +972-73-2507135 info@springnow.com North American Investor Contact: Stephen Kilmer Kilmer Lucas Inc. T: 212-618-6347 stephen@kilmerlucas.com
View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com